IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Additionally, they were able to tune the retention factor for the analytes through isocratic temperature gradient elution. Ideal elutions occurred at 35 °C, but decreasing the temperature to 10 °C or raising it to 50 °C caused faster elutions either way. This is a strong indication that electrostatic and hydrophobic interactions can be similarly affected by changes in temperature. The major advantages from applying these success of this study include stationary phase versatility and maintaining bioactivity of the analytes. Ayano et al. modified PNIPAAm with cationic N,N-dimethylaminopropylacrylamide (DMAPAAm) and hydrophobic BMA and grafted it onto silica beads to form IDB. They used pH changes to adjust the LCST. The effect of pH on the LCST is as follows, from a plateau value between pH 4.5 and pH 6.0, the LCST decreased up to pH 9 and below pH 4.5. This can be interpreted as requiring slightly basic or moderately acidic conditions, as the 4.5–6.0 pH region holds a maximum value of the LCST, an unfavorable condition. They used these properties to separate several non-steroidal anti-inflammatory drugs (NSAIDs). The analysis of acidic drugs (salicylic acid: BA; SA; MS; and As) was performed below pH 4.5. MS is hydrophobic only its retention time was affected by an increase in temperature on the column without a terminally modified anion-exchanger (IB column). However, with an anion-exchanger present, dissociated acidic drugs were retained longer at temperatures below LCST, and shorter at temperatures above LCST.
==== Microwaves ==== A microwave oven, invented in 1950 by U.S. researcher Percy Spencer (1894-1970), is used to quickly heat food using microwave radiation at a frequency of 2.45 gigahertz. In an intact microwave oven, leakage radiation is relatively low due to the shielding of the cooking chamber. An "emission limit of five milliwatts per square centimeter (equivalent to 50 watts per square meter) at a distance of five centimeters from the surface of the appliance" (radiation density or power flux density) is specified. Children should not stand directly in front of or next to the appliance while food is being prepared. In addition, the Federal Office for Radiation Protection lists pregnant women as particularly at risk. In microwave therapy, electromagnetic waves are generated for heat treatment. The penetration depth and energy distribution vary depending on the frequency of application (short waves, ultra short waves, microwaves). To achieve greater penetration, pulsed microwaves are used, each of which delivers high energy to the tissue. A pulse pause ensures that no burns occur. Metal implants and pacemakers are contraindications.
=== Cushing's Disease === Corticotropic cells can have detrimental effects on the body if they express too much or too little ACTH. One such example is Cushing's disease, which can result from overproduction of ACTH in the corticotropes due to pituitary tumors known as corticotroph adenomas; this is the cause for roughly two-thirds of those diagnosed with Cushing's disease. It is also possible that this disease can result from production of ACTH in a non-pituitary tumor, known as ectopic production, or the adrenal glands can overproduce cortisol due to an adrenal tumor. This overproduction of ACTH causes an increase in cortisol levels due to increased glucocorticoid synthesis in the adrenal cortex resulting in several associated symptoms. Symptoms of Cushing's disease include:
Bruck syndrome is characterized as the combination of arthrogryposis multiplex congenita and osteogenesis imperfecta. Both diseases are uncommon, but concurrence is extremely rare which makes Bruck syndrome very difficult to research. Bruck syndrome is thought to be an atypical variant of osteogenesis imperfecta most resembling type III, if not its own disease. Multiple gene mutations associated with osteogenesis imperfecta are not seen in Bruck syndrome. Many affected individuals are within the same family, and pedigree data supports that the disease is acquired through autosomal recessive inheritance. Bruck syndrome has features of congenital contractures, bone fragility, recurring bone fractures, flexion joint and limb deformities, pterygia, short body height, and progressive kyphoscoliosis. Individuals encounter restricted mobility and pulmonary function. A reduction in bone mineral content and larger hydroxyapatite crystals are also detectable Joint contractures are primarily bilateral and symmetrical, and most prone to ankles. Bruck syndrome has no effect on intelligence, vision, or hearing.
=== Legal status === Pethidine is in Schedule II of the Controlled Substances Act 1970 of the United States as a Narcotic with ACSCN 9230 with a 6250 kilo aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.87 for the hydrochloride and 0.84 for the hydrobromide. The A, B, and C intermediates in production of pethidine are also controlled, with ACSCN being 9232 for A (with a 6 gram quota) and 9233 being B (quota of 11 grams) and 9234 being C (6 gram quota). It is listed under the Single Convention for the Control of Narcotic Substances 1961 and is controlled in most countries in the same fashion as is morphine.
Sources: en.wikipedia.org
Regorafenib (marketed under the trade name Stivarga) is currently being studied as a potential treatment option in multiple tumor types. On September 27, 2012, the FDA approved regorafenib for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy. On February 25, 2013, the FDA approved regorafenib in a second indication to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is a compound developed by Bayer. The most common adverse reactions (≥ 20%) are asthenia/fatigue, hand-foot skin reaction (HFSR), diarrhea, decreased appetite/food intake, hypertension, mucositis, dysphonia and infection, pain (not otherwise specified), weight loss, abdominal pain, rash, fever and nausea. In 2011, Bayer entered into an agreement with Onyx under which Onyx will receive a 20 percent royalty on any future global net sales of regorafenib in oncology. Bayer and Onyx jointly promote Stivarga in the United States.
==== Antibiotic Awareness Week ==== The World Health Organization has promoted the first World Antibiotic Awareness Week running from 16 to 22 November 2015. The aim of the week is to increase global awareness of antibiotic resistance. It also wants to promote the correct usage of antibiotics across all fields to prevent further instances of antibiotic resistance. World Antibiotic Awareness Week has been held every November since 2015. For 2017, the Food and Agriculture Organization of the United Nations (FAO), the World Health Organization (WHO) and the World Organisation for Animal Health (OIE) are together calling for responsible use of antibiotics in humans and animals to reduce the emergence of antibiotic resistance. United Nations In 2016, the Secretary-General of the United Nations convened the Interagency Coordination Group (IACG) on Antimicrobial Resistance. The IACG worked with international organizations and experts in human, animal, and plant health to create a plan to fight antimicrobial resistance. Their report released in April 2019 focuses on the seriousness of antimicrobial resistance and the threat it poses to world health. It suggests five recommendations for member states to follow to tackle this increasing threat. The IACG recommendations are as follows:
Most cases have been diagnosed post-mortem following a biopsy of the patient's brain tissue. It takes one to twelve days, median five, for symptoms to appear after nasal exposure to N. fowleri flagellates. Symptoms may include headache, fever, nausea, vomiting, loss of appetite, altered mental state, coma, drooping eyelid, blurred vision, and loss of the sense of taste. Later symptoms may include stiff neck, confusion, lack of attention, loss of balance, seizures, and hallucinations. Once symptoms begin to appear, the patient usually dies within two weeks. N. fowleri is not contagious; an infected person cannot transmit the infection. Primary amoebic meningoencephalitis is classified as a rare disease in the United States, as it affects fewer than 200,000 people. From 2013 to 2022, 29 infections were reported in the US, which compares with about 4,000 annual deaths by drowning. It is so rare that individual cases are often reported internationally, with 381 cases reported globally. The true number of cases is likely to be higher than those reported due to problems related with diagnosis, access to diagnostic testing and a lack of surveillance. Over 40% of all known global cases of primary amoebic meningoencephalitis are reported in the United States. Animals can become infected by Naegleria fowleri. This is rarely observed, although many cases are thought to be overlooked. Experimentally, mice, guinea pigs, and sheep have been infected, and there have been reports of South American tapirs and cattle contracting PAM.
Understanding the igneous petrology of monazite is important to be able to date the crystallisation age of igneous rocks. Monazite is commonly present as an accessory mineral in low-CaO peraluminous granitoids, from diorites, micaceous granites to pegmatites. The reason for the low CaO content is probably that melts with high CaO content promote the formation of apatite and allanite but not monazite. It is commonly formed from magmatism involving carbonatic melts but not mafic plutons or lavas. Those rocks usually host economic REE ore deposits, making monazite geochronology important in mining exploration. The simplest monazite zonation showing successive crystallisation of melts is concentric zonation, in which new monazite layers are crystallized rim-by-rim around the pre-existing core. The rims often show compositional variations due to the preferential incorporation of certain elements in the crystal lattice. For example, considering a closed system, Th is preferentially incorporated into the monazite mineral structure, leaving a Th-depleted melt. Therefore, older monazite near the core of a grain is rich in Th while younger monazite contains less, resulting in a rimward decrease of Th in a concentric zoning pattern. Investigating composition and age variation of these rims help to constrain the timing and rate of crystallisation as well as the composition of the melt, especially for rocks where zircon is not present.
Economist Adam Hanieh argues that, in the post-WWII era, the global capitalist system was destabilized by a wave of decolonization movements that swept through Africa, Asia, and Latin America. According to historian L. S. Stavrianos, inspired by the Soviet Union’s rapid socioeconomic progress, numerous revolutionary governments subsequently implemented state-planned economies and public ownership. In his autobiography, the former Prime Minister of India, Jawaharlal Nehru, proclaimed that "the presence and example of the Soviets was a bright and heartening phenomenon in a dark and dismal world." Political scientist Michael Parenti argues that these revolutionary governments implemented land reform and comprehensive programs for health, education, housing, and employment. By addressing the legacies of colonial exploitation and extreme poverty, he writes, these initiatives resulted in a historically unprecedented rise in the standard of living for hundreds of millions of people. Economist Samir Amin contends that these revolutionary governments also achieved progress in industrialization, economic equality, and the construction of modern states. According to economist Alice Amsden, World Bank data reveal a historic trend between 1950 and 1980: for the first time in recorded history, developing economies outpaced developed economies, achieving an average annual income growth of over 5% compared to 4% in the developed economies.
Sources: en.wikipedia.org
== Methods == There is a range of IQF technologies, but the main concept is to transport the product into the freezer with the help of a processing line belt or infeed shaker. Inside the freezer, the product travels through the freezing zone and exits the other side. Product transport inside the freezer uses different technologies. Some freezers use transport belts similar to a conveyor belt. Others use bed plates that hold the product, and an asymmetrical movement makes the plate advance by itself through the freezer. There are two main IQF technologies: mechanical IQF freezers and cryogenic IQF freezers. Mechanical IQF freezers work on the principle of cold air circulation, which flows from underneath the bed plate or transport belt with the help of fans. The cold airflow passes through the pieces of product in circular motions while the product is also advancing through the freezer towards the exit. The design and efficiency of this type of IQF freezers varies among manufacturers who seek to find the perfect balance of aerodynamics for an optimal freezing result. This technology has seen impressive improvements and developments during the past 20 years, being suited for an increasing range of products. Cryogenic IQF freezers immerse the product in liquid nitrogen at very low temperatures, freezing it rapidly while continuously moving the product to avoid block or lump formation. Although this method shows good freezing results, it might lead to higher processing costs per weight of product due to the cost of the liquid nitrogen required.
A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. (NLM) An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo. (NCI) Placebo controlled study
== Reception == Sowmya Shruthi of The Times of India rated three out of five and wrote "Ninnu Kori is an entertainer with lots of drama and emotion with just the right amount of laughter thrown in," while adding that "Nani, Aadhi and Nivetha breathe life in their characters and you can't think of anybody else playing those roles with such ease and conviction." Firstpost's Hemanth Kumar gave 3.5/5 and praised the film for its well written characters. "Ninnu Kori is a character-driven film and Shiva Nirvana invests plenty of time in developing each of the characters who have to deal with their share of pain and turbulence in their lives", Kumar stated. He also added that "[the film] drives home the notion that love is transient and that in pursuit of happiness, you learn to move on from your past." Sangeetha Devi Dundoo writing for The Hindu opined that "The film is a contemporary take on relationships." Priyanka Sundar of The Indian Express rated two stars out of five, by writing "Shiva Nirvana has presented a love story which initially looked refreshing, but as minutes pass by, the film is too much of stretch with a few laughs thrown in."
== See also == 25-NB Arylcyclohexylamine List of benzimidazole opioids List of orphine opioids List of phenyltropanes Opioid Structural scheduling of synthetic cannabinoids Substituted cathinone Utopioid
=== Progestogens === Progestins (progesterone-like drugs) such as megestrol acetate and medroxyprogesterone acetate have been used for the treatment of hormone-responsive, advanced breast cancer, endometrial cancer, and prostate cancer. Progestins are also used in the treatment of endometrial hyperplasia, a precursor to endometrial adenocarcinoma. The exact mechanism of action of these hormones is unclear, and may involve both direct effect on the tumor cells (suppression of estrogen receptor levels, alteration of hormone metabolism, direct cytotoxicity) and indirect endocrine effects (suppression of adrenal androgen production and plasma estrone sulfate formation).
Sources: en.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.